Two Independent Poster Abstracts Highlighting The Clinical Efficacy of MiMedx Allografts are Recognized at The 2017 Desert Foot Conference

MARIETTA, Ga., Dec. 6, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare, announced today that the Company's products were recognized at the recently completed 2017 Desert Foot, The Annual Multi-Disciplinary Diabetes Limb Salvage Conference Honoring Our Federal Services Healthcare Professionals. The clinical efficacy of MiMedx products were independently studied and were the subject of the poster abstract awarded First Place in the Resident Category and the poster abstract awarded Second Place in the Non-Resident Category.

During the four-day conference held in Phoenix, Arizona from November 29, 2017 through December 2, 2017, the Company's dehydrated Human Amnion/Chorion Membrane (dHACM) allografts were the subject of seven poster abstracts. In addition to the independent study poster abstracts reporting on the results with MiMedx allografts, the Company also sponsored a symposium and two hands-on workshops.

The Desert Foot Conference attracts healthcare professionals from all federal service programs such as the Department of Veterans Affairs (VA) and Department of Defense (DOD), as well as podiatrists, physicians and nurses not associated with the VA or DOD. The programs enable participants to improve limb salvage techniques, improve foot health and to especially diagnose and treat diabetes related disorders of the lower limb. The attendees receive state-of-the-art training on advanced diabetic wound care, surgical procedures, and the frequency, determinants, distribution as well as the diagnosis and treatment of lower extremity diabetic disease.  

The poster abstract on MiMedx dHACM allografts awarded first place in the Resident Category was "The Application of Dehydrated Human Amnion Chorion Membrane (dHACM) Allografts to Expedite Healing in Patients with Six Major Types of Refractory Non-Healing Wounds, 157 Cases," authored by Justin Goldsmith, DPM; Anna Tien, DPM; Aamir Mahmood, DPM; Mike Czurylo, DPM; Laith Shaman, DPM; Kelda Beachy, DPM; Neal Patel, DPM; Shayan Alamgir, DPM; and Matthew Garoufalis, DPM, FASPS, FACFAOM, CWS.

In the Non-Resident Category, the poster abstract on MiMedx dHACM allografts that was awarded second place was "Amniotic Allograft Reduces Joint and Soft Tissue Pain," authored by Christopher Japour, DPM; Praveen Vohra, DPM; Richa Vohra, MD; and Edward Chen, DPM, MD.

MiMedx sponsored the symposium entitled "Using PURION® Processed Placental Tissue Products in the Treatment of Complex, Acute and Chronic Wounds," presented by Matthew Garoufalis, DPM, and Michelle Massee, Manager of Biomedical Research at MiMedx. The hands-on workshop, "Application Techniques and Therapeutic Approaches Using EpiFix, EpiCord & AmnioFix Allografts for Wound Healing and Surgical Procedures," was led by Joseph Terebessy, DPM and David Kyle, DPM. During the Amputation Skills Course, Devin Bland, DPM, led the hands-on workshop entitled "The Use of Amniotic Membrane and Placental Based Tissue Allografts in Limb Salvage Applications."

The remaining five of the seven poster abstracts chronicling independent case studies and respective conclusions relative to MiMedx allografts included:

Parker H. "Pete" Petit, CEO, said, "We are always pleased to participate in this outstanding conference because veterans and current service members have always been a core focus for MiMedx. We are especially honored that our allografts were the subject of these award-winning poster abstracts. Since we began our association with Desert Foot at its 2012 conference, our allografts have been the subject of approximately 60 independent study poster abstracts, and we have sponsored in excess of a dozen symposiums and hands-on workshops for the physicians in attendance. During the last six years, MiMedx has been the Grand Sponsor for two of the annual Desert Foot conferences. We admire the work that Desert Foot does to improve clinical care and we are proud to be associated with this terrific organization."

About MiMedx
MiMedx® is the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. "Innovations in Regenerative Medicine" is the framework behind our mission to give physicians products and tissues to help the body heal itself.  We process the human placental tissue utilizing our proprietary PURION® Process among other processes, to produce safe and effective allografts.  MiMedx proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization.  MiMedx is the leading supplier of placental tissue, having supplied over 1 million allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare. For additional information, please visit www.mimedx.com.

View original content:http://www.prnewswire.com/news-releases/two-independent-poster-abstracts-highlighting-the-clinical-efficacy-of-mimedx-allografts-are-recognized-at-the-2017-desert-foot-conference-300567796.html

SOURCE MiMedx Group, Inc.